文献速递骨软组织肉瘤与黑色素瘤

横纹肌肉瘤的基因组分类与临床结局:国际联盟报告

Genomic Classification and Clinical Outcome in Rhabdomyosarcoma: A Report From an International Consortium.
PubMed 文献 · J Clin Oncol · 2021-06-24

该国际联盟研究对641例横纹肌肉瘤患者肿瘤样本行定制捕获测序,分析驱动突变及其与临床结局的关联。研究发现FOXO1融合阴性病例中RAS通路突变率>50%,TP53突变与更差生存相关,MYOD1突变与不良生存相关,并提供了可检索的ClinOmics数据库。

要点

  • FOXO1融合阴性横纹肌肉瘤中RAS通路突变率超过50%。
  • TP53突变在融合阴性和FOXO1融合阳性病例中均与更差结局相关。
  • MYOD1突变与不良生存及特定临床特征相关。

核心结论

  • 这是迄今最大规模的临床注释横纹肌肉瘤基因组表征,提供了可 refine 风险分层的预后遗传特征并将纳入前瞻性试验。

研究设计与样本

  • 国际联盟研究,对儿童肿瘤协作组试验(1998-2017)和英国恶性间叶肿瘤及RMS2005试验(1995-2016)入组患者的肿瘤样本行定制捕获测序。

主要发现

  • 641例患者DNA适合分析,每肿瘤中位突变数为1。
  • FOXO1融合阴性病例中,>50%存在任何RAS通路成员突变,21%未识别出推定驱动突变。
  • BCOR(15%)、NF1(15%)和TP53(13%)突变发生率高于先前报道,TP53突变在融合阴性和FOXO1融合阳性病例中均与更差结局相关。
  • RAS同种型突变在<1岁婴儿中占主导(64%病例)。
  • MYOD1突变与先前描述之外的组织学模式、较大年龄、头颈部原发部位及极差生存相关。

关键数值与推荐

  • FOXO1融合阴性病例中RAS通路成员突变率>50%。
  • BCOR突变率15%,NF1突变率15%,TP53突变率13%。
  • RAS同种型突变在<1岁婴儿中占64%。

临床怎么用

  • TP53突变状态可用于辅助风险分层,尤其在融合阴性和FOXO1融合阳性病例中。
  • MYOD1突变提示不良生存,需在临床决策中考虑。
  • RAS通路突变在FOXO1融合阴性病例中高发,可能指导未来靶向策略。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Rhabdomyosarcoma is the most common soft tissue sarcoma of childhood. Despite aggressive therapy, the 5-year survival rate for patients with metastatic or recurrent disease remains poor, and beyond PAX-FOXO1 fusion status, no genomic markers are available for risk stratification. We present an international consortium study designed to determine the incidence of driver mutations and their association with clinical outcome. PATIENTS AND METHODS: Tumor samples collected from patients enrolled on Children's Oncology Group trials (1998-2017) and UK patients enrolled on malignant mesenchymal tumor and RMS2005 (1995-2016) trials were subjected to custom-capture sequencing. Mutations, indels, gene deletions, and amplifications were identified, and survival analysis was performed. RESULTS: DNA from 641 patients was suitable for analyses. A median of one mutation was found per tumor. In FOXO1 fusion-negative cases, mutation of any RAS pathway member was found in > 50% of cases, and 21% had no putative driver mutation identified. BCOR (15%), NF1 (15%), and TP53 (13%) mutations were found at a higher incidence than previously reported and TP53 mutations were associated with worse outcomes in both fusion-negative and FOXO1 fusion-positive cases. Interestingly, mutations in RAS isoforms predominated in infants < 1 year (64% of cases). Mutation of MYOD1 was associated with histologic patterns beyond those previously described, older age, head and neck primary site, and a dismal survival. Finally, we provide a searchable companion database (ClinOmics), containing all genomic variants, and clinical annotation including survival data. CONCLUSION: This is the largest genomic characterization of clinically annotated rhabdomyosarcoma tumors to date and provides prognostic genetic features that refine risk stratification and will be incorporated into prospective trials.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Shern JF, Selfe J, Izquierdo E, et al. Genomic Classification and Clinical Outcome in Rhabdomyosarcoma: A Report From an International Consortium. J Clin Oncol. 2021. PMID: 34166060. doi:10.1200/JCO.20.03060

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。